Kevin J. Tu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Kevin J. Tu has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Hem D. Shukla
Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, USA
3 shared publications Cole Wymore
University of Iowa Carver College of Medicine Iowa City Iowa USA
2 shared publicationsJoshua A. Regal
Department of Radiation Oncology, Duke University, Durham, USA
2 shared publications- Matthew S. Waitkus
Department of Neurosurgery, Duke University School of Medicine , Durham (R.H.B., M.S.W.)
2 shared publications - Nicholas Matthew Mohr
Department of Emergency Medicine University of Iowa Carver College of Medicine Iowa City Iowa USA
2 shared publications - Zachary J. Reitman
Duke University School of Medicine
2 shared publications
Latest Publications
- Open Access
- 26 March 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (3) , e0341912
HIF1α mediates resistance to radiation and to KRAS inhibitors in pancreatic adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is highly treatment resistant and characterized by a hypoxic microenvironment. Here, we investigated the role of hypoxia-inducible factor 1α (HIF1α) in regulating resistance to radiation and KRAS-inhibitor. We employed CRISPR/Cas9 to knock out (KO) HIF1α from the murine KRAS G12D/+ ; p53 R172H/+ KPC and the KRAS G12D/+ ; p53 R273H ; CDK2NA -/- Panc-1 human pancreatic cell lines. Compared to WT, the HIF1α KO cell lines demonstrated a shift toward an epithelial phenotype and had decreased proliferation and migration under hypoxia. HIF1α KO cell lines were less likely to survive after radiotherapy, and neutral comet assays demonstrated DNA damage four hours after treatment, suggesting that HIF1α promotes radioresistance through non-homologous end joining. When treated with a KRAS G12D inhibitor, HIF1α KO cells exhibited significantly increased apoptosis due to decreased p53 degradation, likely mediated through Mdm2. Confirming this, enrichment of hypoxic signaling was associated with KRAS inhibitor resistance in a cohort of 31 KRAS G12D cell lines. Our results thus suggest that inhibiting HIF1α may sensitize PDAC to radiation and KRAS inhibitors. To explore this, we conducted a drug repurposing screen and identified three HIF1α inhibitors (bakuchiol, BAY-87–2243, 2-methoxyestradiol) whose sensitivities were correlated with sensitivity to Deltarasin, a KRAS inhibitor. Our findings suggest that HIF1α inhibitors could be used to sensitize PDAC to radiotherapy and KRAS inhibitors.
- 26 March 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (3) , e0341912
Open AccessHIF1α mediates resistance to radiation and to KRAS inhibitors in pancreatic adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is highly treatment resistant and characterized by a hypoxic microenvironment. Here, we investigated the role of hypoxia-inducible factor 1α (HIF1α) in regulating resistance to radiation and KRAS-inhibitor. We employed CRISPR/Cas9 to knock out (KO) HIF1α from the murine KRAS G12D/+ ; p53 R172H/+ KPC and the KRAS G12D/+ ; p53 R273H ; CDK2NA -/- Panc-1 human pancreatic cell lines. Compared to WT, the HIF1α KO cell lines demonstrated a shift toward an epithelial phenotype and had decreased proliferation and migration under hypoxia. HIF1α KO cell lines were less likely to survive after radiotherapy, and neutral comet assays demonstrated DNA damage four hours after treatment, suggesting that HIF1α promotes radioresistance through non-homologous end joining. When treated with a KRAS G12D inhibitor, HIF1α KO cells exhibited significantly increased apoptosis due to decreased p53 degradation, likely mediated through Mdm2. Confirming this, enrichment of hypoxic signaling was associated with KRAS inhibitor resistance in a cohort of 31 KRAS G12D cell lines. Our results thus suggest that inhibiting HIF1α may sensitize PDAC to radiation and KRAS inhibitors. To explore this, we conducted a drug repurposing screen and identified three HIF1α inhibitors (bakuchiol, BAY-87–2243, 2-methoxyestradiol) whose sensitivities were correlated with sensitivity to Deltarasin, a KRAS inhibitor. Our findings suggest that HIF1α inhibitors could be used to sensitize PDAC to radiotherapy and KRAS inhibitors.
- Open Access
- 11 November 2025
- Published by Elsevier in Cell Reports Medicine
- Vol. 6 (11) , 102450
The tumor microenvironment of 14,837 breast cancers is associated with clinical outcome independently of genomic subtypes
- 11 November 2025
- Published by Elsevier in Cell Reports Medicine
- Vol. 6 (11) , 102450
Open AccessThe tumor microenvironment of 14,837 breast cancers is associated with clinical outcome independently of genomic subtypes
- Open Access
- 6 August 2025
- Published by Elsevier in Clinical Biochemistry
- Vol. 139, 110987
Rethinking research funding through a sustainability Lens
- 6 August 2025
- Published by Elsevier in Clinical Biochemistry
- Vol. 139, 110987
Open AccessRethinking research funding through a sustainability Lens
- Open Access
Health damages and disparities from municipal and medical waste incineration in Baltimore, USA
Background: Waste incineration in Baltimore, USA, involves two major facilities: a municipal solid waste incinerator (WIN Waste) and the nation’s largest medical waste incinerator (Curtis Bay Medical Waste Incinerator). Both operate in socio-economically disadvantaged communities, raising concerns about cumulative environmental exposures and health disparities from hazardous air pollutants. Methods: We estimated health impacts from available criteria incinerator emissions data (PM, NOx, SO 2 , CO). We used AERMOD to model ground-level pollutant concentrations, linked these to U.S. Census tracts, and monetized health damages using established relative risk and cost of illness data. Health disparities were evaluated by modeling incinerator-attributable mortality against the Social Vulnerability Index (SVI). Findings: In 2024, the WIN Waste incinerator caused an estimated $53.8 million in health damages in Maryland and Washington DC. On average, the Curtis Bay Medical Waste Incinerator releases black smoke emissions for 52.5 minutes/day, a regulatory violation. The facility causes $36.9 million/year in health damages and is permitted to burn enough waste to cause up to $107.1 million/year; enforcing pollution controls at this site could prevent $13.8 million in annual harm in Baltimore. Combined, the two incinerators cause $97.0 million in damages annually. All-cause mortality from incinerator pollution was more common in communities with higher socioeconomic vulnerability. Interpretation: Despite being required to install new pollution control equipment following community and regulatory pressure, the WIN Waste incinerator still causes significant health damages to Maryland and Washington DC. Meanwhile, repeated black smoke emissions from the Curtis Bay incinerator indicate that ongoing, uncontrolled pollution is also a major threat to public health in the region. Health damages from these incinerators disproportionately affect communities least able to bear the economic burden. Our conservative estimates highlight the need for urgent policy reforms, including stricter emissions monitoring, phasing out non-essential incineration, and ongoing cumulative impact assessments. Funding: KJT and SD were funded by the University of Maryland Baltimore Provost’s Climate Health & Resilience internship program. KJT was supported by a Point Foundation Internship & Professional Development Award and the Alpha Omega Alpha Carolyn L. Kuckein Student Research Fellowship. BS, MAA, and CDH were supported by the National Institute of Environmental Health Sciences (NIEHS) P30 Center for Community Health: Addressing Regional Maryland Environmental Determinants of Disease (CHARMED) [grant no. P30ES032756]. BS, MAA, and CDH were supported by the Johns Hopkins Community Science and Innovation for Environmental Justice (CSI EJ) Initiative. CDH was supported by the National Institute for Occupational Safety and Health (NIOSH) Education and Research Center [grant no. T42OH0008428]. GS and CS are affiliated with the Curtis Bay Community Association and South Baltimore Community Land Trust. The authors have no other conflicts of interest to report.
Open AccessHealth damages and disparities from municipal and medical waste incineration in Baltimore, USA
Background: Waste incineration in Baltimore, USA, involves two major facilities: a municipal solid waste incinerator (WIN Waste) and the nation’s largest medical waste incinerator (Curtis Bay Medical Waste Incinerator). Both operate in socio-economically disadvantaged communities, raising concerns about cumulative environmental exposures and health disparities from hazardous air pollutants. Methods: We estimated health impacts from available criteria incinerator emissions data (PM, NOx, SO 2 , CO). We used AERMOD to model ground-level pollutant concentrations, linked these to U.S. Census tracts, and monetized health damages using established relative risk and cost of illness data. Health disparities were evaluated by modeling incinerator-attributable mortality against the Social Vulnerability Index (SVI). Findings: In 2024, the WIN Waste incinerator caused an estimated $53.8 million in health damages in Maryland and Washington DC. On average, the Curtis Bay Medical Waste Incinerator releases black smoke emissions for 52.5 minutes/day, a regulatory violation. The facility causes $36.9 million/year in health damages and is permitted to burn enough waste to cause up to $107.1 million/year; enforcing pollution controls at this site could prevent $13.8 million in annual harm in Baltimore. Combined, the two incinerators cause $97.0 million in damages annually. All-cause mortality from incinerator pollution was more common in communities with higher socioeconomic vulnerability. Interpretation: Despite being required to install new pollution control equipment following community and regulatory pressure, the WIN Waste incinerator still causes significant health damages to Maryland and Washington DC. Meanwhile, repeated black smoke emissions from the Curtis Bay incinerator indicate that ongoing, uncontrolled pollution is also a major threat to public health in the region. Health damages from these incinerators disproportionately affect communities least able to bear the economic burden. Our conservative estimates highlight the need for urgent policy reforms, including stricter emissions monitoring, phasing out non-essential incineration, and ongoing cumulative impact assessments. Funding: KJT and SD were funded by the University of Maryland Baltimore Provost’s Climate Health & Resilience internship program. KJT was supported by a Point Foundation Internship & Professional Development Award and the Alpha Omega Alpha Carolyn L. Kuckein Student Research Fellowship. BS, MAA, and CDH were supported by the National Institute of Environmental Health Sciences (NIEHS) P30 Center for Community Health: Addressing Regional Maryland Environmental Determinants of Disease (CHARMED) [grant no. P30ES032756]. BS, MAA, and CDH were supported by the Johns Hopkins Community Science and Innovation for Environmental Justice (CSI EJ) Initiative. CDH was supported by the National Institute for Occupational Safety and Health (NIOSH) Education and Research Center [grant no. T42OH0008428]. GS and CS are affiliated with the Curtis Bay Community Association and South Baltimore Community Land Trust. The authors have no other conflicts of interest to report.
- Open Access
- 26 June 2024
- Published by Wiley in The Journal of Rural Health
- Vol. 41 (1)
Provider‐to‐provider telemedicine for sepsis is used less frequently in communities with high social vulnerability
Purpose: Sepsis disproportionately affects patients in rural and socially vulnerable communities. A promising strategy to address this disparity is provider‐to‐provider emergency department (ED)‐based telehealth consultation (tele‐ED). The objective of this study was to determine if county‐level social vulnerability index (SVI) was associated with tele‐ED use for sepsis and, if so, which SVI elements were most strongly associated. Methods: We used data from the TELEmedicine as a Virtual Intervention for Sepsis in Rural Emergency Department study. The primary exposures were SVI aggregate and component scores. We used multivariable generalized estimating equations to model the association between SVI and tele‐ED use. Findings: Our study cohort included 1191 patients treated in 23 Midwestern rural EDs between August 2016 and June 2019, of whom 326 (27.4%) were treated with tele‐ED. Providers in counties with a high SVI were less likely to use tele‐ED (adjusted odds ratio [aOR] = 0.51, 95% confidence interval [CI] 0.31‒0.87), an effect principally attributable to the housing type and transportation component of SVI (aOR = 0.44, 95% CI 0.22–0.89). Providers who treated fewer sepsis patients (1‒10 vs. 31+ over study period) and therefore may have been less experienced in sepsis care, were more likely to activate tele‐ED (aOR = 3.91, 95% CI 2.08‒7.38). Conclusions: Tele‐ED use for sepsis was lower in socially vulnerable counties and higher among providers who treated fewer sepsis patients. These findings suggest that while tele‐ED increases access to specialized care, it may not completely ameliorate sepsis disparities due to its less frequent use in socially vulnerable communities.
- 26 June 2024
- Published by Wiley in The Journal of Rural Health
- Vol. 41 (1)
Open AccessProvider‐to‐provider telemedicine for sepsis is used less frequently in communities with high social vulnerability
Purpose: Sepsis disproportionately affects patients in rural and socially vulnerable communities. A promising strategy to address this disparity is provider‐to‐provider emergency department (ED)‐based telehealth consultation (tele‐ED). The objective of this study was to determine if county‐level social vulnerability index (SVI) was associated with tele‐ED use for sepsis and, if so, which SVI elements were most strongly associated. Methods: We used data from the TELEmedicine as a Virtual Intervention for Sepsis in Rural Emergency Department study. The primary exposures were SVI aggregate and component scores. We used multivariable generalized estimating equations to model the association between SVI and tele‐ED use. Findings: Our study cohort included 1191 patients treated in 23 Midwestern rural EDs between August 2016 and June 2019, of whom 326 (27.4%) were treated with tele‐ED. Providers in counties with a high SVI were less likely to use tele‐ED (adjusted odds ratio [aOR] = 0.51, 95% confidence interval [CI] 0.31‒0.87), an effect principally attributable to the housing type and transportation component of SVI (aOR = 0.44, 95% CI 0.22–0.89). Providers who treated fewer sepsis patients (1‒10 vs. 31+ over study period) and therefore may have been less experienced in sepsis care, were more likely to activate tele‐ED (aOR = 3.91, 95% CI 2.08‒7.38). Conclusions: Tele‐ED use for sepsis was lower in socially vulnerable counties and higher among providers who treated fewer sepsis patients. These findings suggest that while tele‐ED increases access to specialized care, it may not completely ameliorate sepsis disparities due to its less frequent use in socially vulnerable communities.
- Open Access
- 10 November 2023
- Published by Springer Nature in Communications Biology
- Vol. 6 (1) , 1-11
Mining cancer genomes for change-of-metabolic-function mutations
Enzymes with novel functions are needed to enable new organic synthesis techniques. Drawing inspiration from gain-of-function cancer mutations that functionally alter proteins and affect cellular metabolism, we developed METIS (Mutated Enzymes from Tumors In silicoScreen). METIS identifies metabolism-altering cancer mutations using mutation recurrence rates and protein structure. We used METIS to screen 298,517 cancer mutations and identify 48 candidate mutations, including those previously identified to alter enzymatic function. Unbiased metabolomic profiling of cells exogenously expressing a candidate mutant (OGDHLp.A400T) supports an altered phenotype that boosts in vitro production of xanthosine, a pharmacologically useful chemical that is currently produced using unsustainable, water-intensive methods. We then applied METIS to 49 million cancer mutations, yielding a refined set of candidates that may impart novel enzymatic functions or contribute to tumor progression. Thus, METIS can be used to identify and catalog potentially-useful cancer mutations for green chemistry and therapeutic applications.
- 10 November 2023
- Published by Springer Nature in Communications Biology
- Vol. 6 (1) , 1-11
Open AccessMining cancer genomes for change-of-metabolic-function mutations
Enzymes with novel functions are needed to enable new organic synthesis techniques. Drawing inspiration from gain-of-function cancer mutations that functionally alter proteins and affect cellular metabolism, we developed METIS (Mutated Enzymes from Tumors In silicoScreen). METIS identifies metabolism-altering cancer mutations using mutation recurrence rates and protein structure. We used METIS to screen 298,517 cancer mutations and identify 48 candidate mutations, including those previously identified to alter enzymatic function. Unbiased metabolomic profiling of cells exogenously expressing a candidate mutant (OGDHLp.A400T) supports an altered phenotype that boosts in vitro production of xanthosine, a pharmacologically useful chemical that is currently produced using unsustainable, water-intensive methods. We then applied METIS to 49 million cancer mutations, yielding a refined set of candidates that may impart novel enzymatic functions or contribute to tumor progression. Thus, METIS can be used to identify and catalog potentially-useful cancer mutations for green chemistry and therapeutic applications.
- 11 October 2023
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 100 (2) , 256-267
Docetaxel radiosensitizes castration-resistant prostate cancer by downregulating CAV-1
Purpose: Docetaxel (dox), a noted radiosensitizer, is one of the few chemotherapy drugs approved for castration-resistant prostate cancer (CRPC), though only a fraction of CRPCs respond to it. CAV-1, a critical regulator of radioresistance, has been known to modulate dox and radiation effects. Combining dox with radiotherapy may create a synergistic anticancer effect through CAV-1 and improve CRPC patients' response to therapy. Here, we investigate the effectiveness and molecular characteristics of dox and radiation combination therapy in vitro.Materials and Methods: We used live/dead assays to determine the IC50 of dox for PC3, DU-145, and TRAMP-C1 cells. Colony formation assay was used to determine the radioresponse of the same cells treated with radiation with/without IC50 dox (4, 8, 12 Gy). We performed gene expression analysis on public transcriptomic data collected from human-derived prostate cancer cell lines (C4-2, PC3, DU-145, LNCaP) treated with dox for 8, 16, and 72 hours. Cell cycle arrest and protein expression were assessed using flow cytometry and western blot, respectively.Results: Compared to radiation alone, combination therapy with dox significantly increased CRPC death in PC3 (1.48-fold, p < 0.0001), DU-145 (1.64-fold, p < 0.05), and TRAMP-C1 (1.13-fold, p < 0.05) at 4 Gy of radiation. Gene expression of CRPC treated with dox revealed downregulated genes related to cell cycle regulation and upregulated genes related to immune activation and oxidative stress. Confirming the results, G2/M cell cycle arrest was significantly increased after treatment with dox and radiation. CAV-1 protein expression was decreased after dox treatment in a dose-dependent manner; furthermore, CAV-1 copy number was strongly associated with poor response to therapy in CRPC patients.Conclusions: Our results suggest that dox sensitizes CRPC cells to radiation by downregulating CAV-1. Dox + radiation combination therapy may be effective at treating CRPC, especially subtypes associated with high CAV-1 expression, and should be studied further.
- 11 October 2023
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 100 (2) , 256-267
Docetaxel radiosensitizes castration-resistant prostate cancer by downregulating CAV-1
Purpose: Docetaxel (dox), a noted radiosensitizer, is one of the few chemotherapy drugs approved for castration-resistant prostate cancer (CRPC), though only a fraction of CRPCs respond to it. CAV-1, a critical regulator of radioresistance, has been known to modulate dox and radiation effects. Combining dox with radiotherapy may create a synergistic anticancer effect through CAV-1 and improve CRPC patients' response to therapy. Here, we investigate the effectiveness and molecular characteristics of dox and radiation combination therapy in vitro.Materials and Methods: We used live/dead assays to determine the IC50 of dox for PC3, DU-145, and TRAMP-C1 cells. Colony formation assay was used to determine the radioresponse of the same cells treated with radiation with/without IC50 dox (4, 8, 12 Gy). We performed gene expression analysis on public transcriptomic data collected from human-derived prostate cancer cell lines (C4-2, PC3, DU-145, LNCaP) treated with dox for 8, 16, and 72 hours. Cell cycle arrest and protein expression were assessed using flow cytometry and western blot, respectively.Results: Compared to radiation alone, combination therapy with dox significantly increased CRPC death in PC3 (1.48-fold, p < 0.0001), DU-145 (1.64-fold, p < 0.05), and TRAMP-C1 (1.13-fold, p < 0.05) at 4 Gy of radiation. Gene expression of CRPC treated with dox revealed downregulated genes related to cell cycle regulation and upregulated genes related to immune activation and oxidative stress. Confirming the results, G2/M cell cycle arrest was significantly increased after treatment with dox and radiation. CAV-1 protein expression was decreased after dox treatment in a dose-dependent manner; furthermore, CAV-1 copy number was strongly associated with poor response to therapy in CRPC patients.Conclusions: Our results suggest that dox sensitizes CRPC cells to radiation by downregulating CAV-1. Dox + radiation combination therapy may be effective at treating CRPC, especially subtypes associated with high CAV-1 expression, and should be studied further.
- 23 September 2023
- Published by Springer Nature in Oncogene
- Vol. 42 (44) , 3274-3286
Pooled genetic screens to identify vulnerabilities in TERT-promoter-mutant glioblastoma
Pooled genetic screens represent a powerful approach to identify vulnerabilities in cancer. Here we used pooled CRISPR/Cas9-based approaches to identify vulnerabilities associated with telomerase reverse transcriptase (TERT) promoter mutations (TPMs) found in >80% of glioblastomas. We first developed a platform to detect perturbations that cause long-term growth defects in a TPM-mutated glioblastoma cell line. However, we could not detect dependencies on either TERT itself or on an E-twenty six transcription (ETS) factor known to activate TPMs. To explore this finding, we cataloged TPM status for 441 cell lines and correlated this with genome-wide screening data. We found that TPM status was not associated with differential dependency on TERT, but that E-twenty six (ETS) transcription factors represent key dependencies in both TPM+ and TPM- lines. Further, we found that TPMs are associated with expression of gene programs regulated by a wide array of ETS-factors in both cell lines and primary glioblastoma tissues. This work contributes a unique TPM cell line reagent, establishes TPM status for many deeply-profiled cell lines, and catalogs TPM-associated vulnerabilities. The results highlight challenges in executing genetic screens to detect TPM-specific vulnerabilities, and suggest redundancy in the genetic network that regulates TPM function with therapeutic implications.
- 23 September 2023
- Published by Springer Nature in Oncogene
- Vol. 42 (44) , 3274-3286
Pooled genetic screens to identify vulnerabilities in TERT-promoter-mutant glioblastoma
Pooled genetic screens represent a powerful approach to identify vulnerabilities in cancer. Here we used pooled CRISPR/Cas9-based approaches to identify vulnerabilities associated with telomerase reverse transcriptase (TERT) promoter mutations (TPMs) found in >80% of glioblastomas. We first developed a platform to detect perturbations that cause long-term growth defects in a TPM-mutated glioblastoma cell line. However, we could not detect dependencies on either TERT itself or on an E-twenty six transcription (ETS) factor known to activate TPMs. To explore this finding, we cataloged TPM status for 441 cell lines and correlated this with genome-wide screening data. We found that TPM status was not associated with differential dependency on TERT, but that E-twenty six (ETS) transcription factors represent key dependencies in both TPM+ and TPM- lines. Further, we found that TPMs are associated with expression of gene programs regulated by a wide array of ETS-factors in both cell lines and primary glioblastoma tissues. This work contributes a unique TPM cell line reagent, establishes TPM status for many deeply-profiled cell lines, and catalogs TPM-associated vulnerabilities. The results highlight challenges in executing genetic screens to detect TPM-specific vulnerabilities, and suggest redundancy in the genetic network that regulates TPM function with therapeutic implications.
- 24 April 2023
- Published by SAGE Publications in Journal of Telemedicine and Telecare
- Vol. 31 (1) , 3-13
The impact of telehealth in sepsis care: A systematic review
Objectives: Sepsis is associated with significant mortality. Telehealth may improve the quality of early sepsis care, but the use and impact of telehealth applications for sepsis remain unclear. We aim to describe the telehealth interventions that have been used to facilitate sepsis care, and to summarize the reported effect of telehealth on sepsis outcomes. Data Sources: We identified articles reporting telehealth use for sepsis using an English-language search of PubMed, CINAHL Plus (EBSCO), Academic Search Ultimate (EBSCO), APA PsycINFO (EBSCO), Public Health (ProQuest), and Web of Science databases with no restrictions on publication date. Study Selection: Included studies described the use of telehealth as an intervention for treating sepsis. Only comparative effectiveness analyses were included. Data Extraction and Synthesis: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews (PRISMA-ScR) guidelines, two investigators independently selected articles for inclusion and abstracted data. A random-effects subgroup analysis was conducted on patient survival treated with and without telehealth. Results: A total of 15 studies were included, involving 188,418 patients with sepsis. Thirteen studies used observational study designs, and the most common telehealth applications were provider-to-provider telehealth consultation and intensive care unit telehealth. Clinical and methodological heterogeneity was significantly high. Telehealth use was associated with higher survival, especially in settings with low control group survival. The effect of telehealth on other care processes and outcomes were more varied and likely dependent on hospital-level factors. Conclusions: Telehealth has been used in diverse applications for sepsis care, and it may improve patient outcomes in certain contexts. Additional interventional trials and cost-based analyses would clarify the causal role of telehealth in improving sepsis outcomes.
- 24 April 2023
- Published by SAGE Publications in Journal of Telemedicine and Telecare
- Vol. 31 (1) , 3-13
The impact of telehealth in sepsis care: A systematic review
Objectives: Sepsis is associated with significant mortality. Telehealth may improve the quality of early sepsis care, but the use and impact of telehealth applications for sepsis remain unclear. We aim to describe the telehealth interventions that have been used to facilitate sepsis care, and to summarize the reported effect of telehealth on sepsis outcomes. Data Sources: We identified articles reporting telehealth use for sepsis using an English-language search of PubMed, CINAHL Plus (EBSCO), Academic Search Ultimate (EBSCO), APA PsycINFO (EBSCO), Public Health (ProQuest), and Web of Science databases with no restrictions on publication date. Study Selection: Included studies described the use of telehealth as an intervention for treating sepsis. Only comparative effectiveness analyses were included. Data Extraction and Synthesis: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews (PRISMA-ScR) guidelines, two investigators independently selected articles for inclusion and abstracted data. A random-effects subgroup analysis was conducted on patient survival treated with and without telehealth. Results: A total of 15 studies were included, involving 188,418 patients with sepsis. Thirteen studies used observational study designs, and the most common telehealth applications were provider-to-provider telehealth consultation and intensive care unit telehealth. Clinical and methodological heterogeneity was significantly high. Telehealth use was associated with higher survival, especially in settings with low control group survival. The effect of telehealth on other care processes and outcomes were more varied and likely dependent on hospital-level factors. Conclusions: Telehealth has been used in diverse applications for sepsis care, and it may improve patient outcomes in certain contexts. Additional interventional trials and cost-based analyses would clarify the causal role of telehealth in improving sepsis outcomes.
- Open Access
- 17 December 2022
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 17 (1) , 1-23
Amyloid-beta and tau pathologies act synergistically to induce novel disease stage-specific microglia subtypes
Background: Amongst risk alleles associated with late-onset Alzheimer’s disease (AD), those that converged on the regulation of microglia activity have emerged as central to disease progression. Yet, how canonical amyloid-β (Aβ) and tau pathologies regulate microglia subtypes during the progression of AD remains poorly understood. Methods: We use single-cell RNA-sequencing to profile microglia subtypes from mice exhibiting both Aβ and tau pathologies across disease progression. We identify novel microglia subtypes that are induced in response to both Aβ and tau pathologies in a disease-stage-specific manner. To validate the observation in AD mouse models, we also generated a snRNA-Seq dataset from the human superior frontal gyrus (SFG) and entorhinal cortex (ERC) at different Braak stages. Results: We show that during early-stage disease, interferon signaling induces a subtype of microglia termed Early-stage AD-Associated Microglia (EADAM) in response to both Aβ and tau pathologies. During late-stage disease, a second microglia subtype termed Late-stage AD-Associated Microglia (LADAM) is detected. While similar microglia subtypes are observed in other models of neurodegenerative disease, the magnitude and composition of gene signatures found in EADAM and LADAM are distinct, suggesting the necessity of both Aβ and tau pathologies to elicit their emergence. Importantly, the pattern of EADAM- and LADAM-associated gene expression is observed in microglia from AD brains, during the early (Braak II)- or late (Braak VI/V)- stage of the disease, respectively. Furthermore, we show that several Siglec genes are selectively expressed in either EADAM or LADAM. Siglecg is expressed in white-matter-associated LADAM, and expression of Siglec-10, the human orthologue of Siglecg, is progressively elevated in an AD-stage-dependent manner but not shown in non-AD tauopathy. Conclusions: Using scRNA-Seq in mouse models bearing amyloid-β and/or tau pathologies, we identify novel microglia subtypes induced by the combination of Aβ and tau pathologies in a disease stage-specific manner. Our findings suggest that both Aβ and tau pathologies are required for the disease stage-specific induction of EADAM and LADAM. In addition, we revealed Siglecs as biomarkers of AD progression and potential therapeutic targets.
- 17 December 2022
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 17 (1) , 1-23
Open AccessAmyloid-beta and tau pathologies act synergistically to induce novel disease stage-specific microglia subtypes
Background: Amongst risk alleles associated with late-onset Alzheimer’s disease (AD), those that converged on the regulation of microglia activity have emerged as central to disease progression. Yet, how canonical amyloid-β (Aβ) and tau pathologies regulate microglia subtypes during the progression of AD remains poorly understood. Methods: We use single-cell RNA-sequencing to profile microglia subtypes from mice exhibiting both Aβ and tau pathologies across disease progression. We identify novel microglia subtypes that are induced in response to both Aβ and tau pathologies in a disease-stage-specific manner. To validate the observation in AD mouse models, we also generated a snRNA-Seq dataset from the human superior frontal gyrus (SFG) and entorhinal cortex (ERC) at different Braak stages. Results: We show that during early-stage disease, interferon signaling induces a subtype of microglia termed Early-stage AD-Associated Microglia (EADAM) in response to both Aβ and tau pathologies. During late-stage disease, a second microglia subtype termed Late-stage AD-Associated Microglia (LADAM) is detected. While similar microglia subtypes are observed in other models of neurodegenerative disease, the magnitude and composition of gene signatures found in EADAM and LADAM are distinct, suggesting the necessity of both Aβ and tau pathologies to elicit their emergence. Importantly, the pattern of EADAM- and LADAM-associated gene expression is observed in microglia from AD brains, during the early (Braak II)- or late (Braak VI/V)- stage of the disease, respectively. Furthermore, we show that several Siglec genes are selectively expressed in either EADAM or LADAM. Siglecg is expressed in white-matter-associated LADAM, and expression of Siglec-10, the human orthologue of Siglecg, is progressively elevated in an AD-stage-dependent manner but not shown in non-AD tauopathy. Conclusions: Using scRNA-Seq in mouse models bearing amyloid-β and/or tau pathologies, we identify novel microglia subtypes induced by the combination of Aβ and tau pathologies in a disease stage-specific manner. Our findings suggest that both Aβ and tau pathologies are required for the disease stage-specific induction of EADAM and LADAM. In addition, we revealed Siglecs as biomarkers of AD progression and potential therapeutic targets.